Koers Cellectar Biosciences Inc Nasdaq
Aandelen
US15117F2039
Farmaceutische producten
slotkoers
Andere beurzen
|
||
- USD | - |
28/03 | CELLECTAR BIOSCIENCES, INC. : Roth MKM handhaaft koopadvies | ZM |
28/03 | CELLECTAR BIOSCIENCES, INC. : Oppenheimer handhaaft koopadvies | ZM |
Omzet 2024 * | - | Omzet 2025 * | 44,27 mln. 41,14 mln. | Marktkapitalisatie | 123 mln. 114 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -49 mln. -45,54 mln. | Nettowinst (verlies) 2025 * | -22 mln. -20,44 mln. | EV/omzet 2024 * | - |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 2,77 x |
K/w-verhouding 2024 * |
-2,09
x | K/w-verhouding 2025 * |
-5,93
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 88,19% |
Recentste transcriptie over Cellectar Biosciences Inc
Managers | Titel | Leeftijd | Van |
---|---|---|---|
James V. Caruso
CEO | Chief Executive Officer | 65 | 15-06-15 |
Chad J. Kolean
DFI | Director of Finance/CFO | 59 | 28-05-14 |
Andrei Shustov
CTO | Chief Tech/Sci/R&D Officer | - | 15-02-23 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Fred Driscoll
BRD | Director/Board Member | 74 | 07-04-17 |
Douglas Swirsky
CHM | Chairman | 54 | 07-04-17 |
John Neis
BRD | Director/Board Member | 68 | 01-02-08 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+26,08% | 662 mld. | |
+21,85% | 546 mld. | |
-4,77% | 359 mld. | |
+16,97% | 323 mld. | |
+5,69% | 290 mld. | |
+13,68% | 234 mld. | |
+3,65% | 198 mld. | |
-11,12% | 194 mld. | |
-3,40% | 157 mld. |
- Beurs
- Aandelen
- Koers CLRB
- Koers